Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus RESNIBEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus RESNIBEN.
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE vs RESNIBEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azilsartan medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing sodium and water excretion.
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg or 25 mg orally once daily; maximum dose: azilsartan medoxomil 40 mg/chlorthalidone 25 mg per day.
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
None Documented
None Documented
Azilsartan medoxomil: Terminal half-life approximately 11 hours. Chlorthalidone: Long terminal half-life of 40-60 hours (mean 47 hours), allowing once-daily dosing.
Terminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min).
Azilsartan medoxomil: Approximately 55% of the dose is excreted in feces and 42% in urine, mostly as metabolites. Chlorthalidone: Primarily excreted unchanged in urine (50-70%) via tubular secretion; approximately 30% is excreted in feces via biliary elimination.
Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic